| Literature DB >> 21320612 |
Xue Hua1, Boris Gutman1, Christina P Boyle1, Priya Rajagopalan1, Alex D Leow2, Igor Yanovsky1, Anand R Kumar3, Arthur W Toga1, Clifford R Jack4, Norbert Schuff5, Gene E Alexander6, Kewei Chen7, Eric M Reiman8, Michael W Weiner9, Paul M Thompson10.
Abstract
This paper responds to Thompson and Holland (2011), who challenged our tensor-based morphometry (TBM) method for estimating rates of brain changes in serial MRI from 431 subjects scanned every 6 months, for 2 years. Thompson and Holland noted an unexplained jump in our atrophy rate estimates: an offset between 0 and 6 months that may bias clinical trial power calculations. We identified why this jump occurs and propose a solution. By enforcing inverse-consistency in our TBM method, the offset dropped from 1.4% to 0.28%, giving plausible anatomical trajectories. Transitivity error accounted for the minimal remaining offset. Drug trial sample size estimates with the revised TBM-derived metrics are highly competitive with other methods, though higher than previously reported sample size estimates by a factor of 1.6 to 2.4. Importantly, estimates are far below those given in the critique. To demonstrate a 25% slowing of atrophic rates with 80% power, 62 AD and 129 MCI subjects would be required for a 2-year trial, and 91 AD and 192 MCI subjects for a 1-year trial.Entities:
Year: 2011 PMID: 21320612 PMCID: PMC3394184 DOI: 10.1016/j.neuroimage.2011.01.079
Source DB: PubMed Journal: Neuroimage ISSN: 1053-8119 Impact factor: 6.556